ClinicalTrials.gg
RecruitingNCT06598397Updated Nov 12, 2026

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

A Phase 4 interventional study of Motivational Interviewing (MI) Counseling and Peer Mentoring in Human Immunodeficiency Virus (HIV) and Smoking Cessation, sponsored by New York University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionSmoking CessationRegistry: Acquired Immunodeficiency SyndromeReclassifiedWhy we changed it
Registry
Acquired Immunodeficiency Syndrome — the first condition term the registry derived for this study.
ClinicalTrials.gg
Smoking Cessation
Why
  1. The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Smoking Cessation.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by New York University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 12, 2026Study documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 921 studies in Smoking Cessation with a site in United States — 98 open to participants now, 127 under way, 7 of them phase 3. Smoking Cessation · United States.

Planned enrollment
209th of 873
500 · median 148
Started
2024
with 44 others
Phase 4
99 of 921
7 open now
Primary completion
2028-06
later than 100 of 126 live
Registered
852nd of 921
by date

Among the 921 studies in Smoking Cessation with a site in United States, this one is the 209th largest by planned enrollment of the 873 interventional ones that give a count, is one of 45 that started in 2024, is one of 99 in phase 4, reaches primary completion later than 100 of the 126 other live ones, and was the 852nd registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

98 of the 921 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 921 studies in Smoking Cessation with a site in United States, or all of them as a file.
02

Study summary

This study's long-term goal is to improve clinical outcomes among smokers living with HIV (SLWH) by providing smoking cessation interventions in HIV clinical care that will increase the chances of quitting smoking, limits costs and burden on staff and reach many smokers living with HIV.

Read the detailed description

This study will utilize Multiphase Optimization Strategy (MOST) to optimize a smoking cessation treatment for HIV clinical care by directly targeting patient barriers to quitting and clinical care barriers to reaching and effectively treating a broad heterogeneous population of smokers living with HIV. The four intervention components will be aimed at barriers to quitting among smokers living with HIV and include Motivational Interviewing; Peer Mentoring; Text-messaging; Combination Nicotine Replacement Therapy. These components have shown promise in research but are under-utilized to help smokers living with HIV quit and have not been tested in an optimization trial. This study will also incorporate data to evaluate the fidelity, acceptability and feasibility of the interventions in the HIV clinical care context in order to identify the most cost-effective, sustainable and scalable tobacco treatment package for the care environment.

03

Conditions studied

  • Human Immunodeficiency Virus (HIV)
  • Smoking Cessation

Browse trials for

Keywords

  • MOST
  • multiphase optimization strategy
  • implementation
  • HIV clinical care
04

In context

Smoking Cessation Reclassified

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

This study's planned enrollment of 500 is above the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.

Browse Smoking Cessation studies →

Lead sponsor

New York University is the lead sponsor of 124 studies on the registry; 32 are open to participants now.

Compared within Smoking Cessation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Status as +
  • Age 18 or older
  • Currently smokes ≥ 5 CPD, on average, in past month
  • Positive for salivary cotinine
  • Able to understand the nature of the study and the consenting process
  • Is engaged in HIV clinical care
  • Living in larger NYC metropolitan area currently and for the next 6-8 months

Exclusion criteria

Exclusion Criteria:

  • Suffers from any medical condition or precluding use of nicotine replacement therapy
  • Current use of any tobacco cessation medications (varenicline, NRT patch, nicotine gum, lozenge, spray or inhaler, or bupropion)
  • Currently participating in a smoking cessation program
  • Pregnant or nursing and plans to be in next 6 months
  • Has schizophrenia/schizo-affective disorder
  • Does not have a functioning mobile phone that can receive text messages
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • No intervention
    Condition 1

    Participants will receive the Core Component.

  • Experimental
    Condition 2

    Participants will receive the Core Component and Combination-NRT intervention.

    Drug: Combination NRT

  • Experimental
    Condition 3

    Participants will receive the Core Component and Text Messaging intervention.

    Behavioral: Skills-based Text Messaging

  • Experimental
    Condition 4

    Participants will receive the Core Component as well as the Combination-NRT and Text Messaging interventions.

    Behavioral: Skills-based Text Messaging · Drug: Combination NRT

  • Experimental
    Condition 5

    Participants will receive the Core Component and Peer Mentoring intervention.

    Behavioral: Peer Mentoring

  • Experimental
    Condition 6

    Participants will receive the Core Component as well as the Combination-NRT and Peer Mentoring interventions.

    Behavioral: Peer Mentoring · Drug: Combination NRT

  • Experimental
    Condition 7

    Participants will receive the Core Component as well as the Text Messaging and Peer Mentoring interventions.

    Behavioral: Peer Mentoring · Behavioral: Skills-based Text Messaging

  • Experimental
    Condition 8

    Participants will receive the Core Component as well as the Combination-NRT, Text Messaging and Peer Mentoring interventions.

    Behavioral: Peer Mentoring · Behavioral: Skills-based Text Messaging · Drug: Combination NRT

  • Experimental
    Condition 9

    Participants will receive the Core Component and Motivational Interviewing Counseling intervention.

    Behavioral: Motivational Interviewing (MI) Counseling

  • Experimental
    Condition 10

    Participants will receive the Core Component as well as the Combination-NRT and Motivational Interview Counseling interventions.

    Behavioral: Motivational Interviewing (MI) Counseling · Drug: Combination NRT

  • Experimental
    Condition 11

    Participants will receive the Core Component as well as the Text Messaging and Motivational Interview Counseling interventions.

    Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Skills-based Text Messaging

  • Experimental
    Condition 12

    Participants will receive the Core Component as well as the Combination-NRT, Text Messaging and Motivational Interview Counseling interventions.

    Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Skills-based Text Messaging · Drug: Combination NRT

  • Experimental
    Condition 13

    Participants will receive the Core Component as well as the Peer Mentoring and Motivational Interview Counseling interventions.

    Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Peer Mentoring

  • Experimental
    Condition 14

    Participants will receive the Core Component as well as the Combination-NRT, Peer Mentoring and Motivational Interview Counseling interventions.

    Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Peer Mentoring · Drug: Combination NRT

  • Experimental
    Condition 15

    Participants will receive the Core Component as well as the Text Messaging, Peer Mentoring and Motivational Interview Counseling interventions.

    Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Peer Mentoring · Behavioral: Skills-based Text Messaging

  • Experimental
    Condition 16

    Participants will receive the Core Component as well as the Combination-NRT, Text Messaging, Peer Mentoring, and Motivational Interview Counseling interventions.

    Behavioral: Motivational Interviewing (MI) Counseling · Behavioral: Peer Mentoring · Behavioral: Skills-based Text Messaging · Drug: Combination NRT

Interventions

  • BehavioralMotivational Interviewing (MI) Counseling

    Six sessions of phone counseling over 10-12 weeks with MI counselor trained in motivational interviewing and tobacco use treatment.

  • BehavioralPeer Mentoring

    Eight sessions of informal counseling with an experienced peer former smoker living with HIV to model healthy behavior and provide practical advice and tips for quitting based on their lived experience.

  • BehavioralSkills-based Text Messaging

    NCI's 8-week text messaging smoking cessation program, smokefreeTXT.gov.

  • DrugCombination NRT

    If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.

07

What researchers measure

Primary outcomes

  1. Biochemically-validated 7-day point prevalence smoking abstinence among SLWH in HIV clinical care

    Self-reported 7-day cigarette PPA (point prevalence abstinence), with biochemical verification of CO (carbon monoxide) ≤6 ppm and negative salivary cotinine

    Time frame: 32 weeks

Secondary outcomes

  1. Self-reported 30-day PPA

    Self-reported 30-day cigarette PPA (point prevalence abstinence)

    Time frame: 32 weeks

  2. Self-reported 7-day PPA

    Self-reported 7-day cigarette PPA (point prevalence abstinence) with carbon monoxide verification (\<=6 ppm)

    Time frame: 8 and 16 weeks

  3. Self-reported 30-day PPA

    Self-reported 30-day cigarette PPA (point prevalence abstinence)

    Time frame: 8 and 16 weeks

  4. Quit attempts

    Number of quit attempts (of at least 24 hours) in last 7 days and since last assessment

    Time frame: 8, 16, and 32 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2028, 44 months after the start.

Of 53 non-industry phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 44 months is above that.

Counting every sponsor, half of 56 studies reached it within 35 months; a quarter within 21 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Sep 19, 2024
StartActual
Oct 18, 2024
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Documents
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Documents Informed consent form ↗ updated

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06598397
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 18, 2024
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Jennifer Cantrell, DrPH, MPA
Contact
jennifer.cantrell@nyu.edu
212-998-5797

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion